StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson INVOKANA / INVOKAMET [reported separately through by Quarter

INVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

Johnson & Johnson INVOKANA / INVOKAMET [reported separately through: -19.6% in Q4 2022, up 25.3 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2022
-19.6%
Period ended Jan 1, 2023
Change on a year earlier
+25.3 pts
-44.9% in Q4 2021
History
21 quarters
Since Q4 2017
Sources
21
Documents cited below

Where the Q4 2022 figure comes from

“|| WW | 91 | 120 | (24.1) | (19.6) | (4.5)”

Source: Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗

Reported in Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedINVOKANA / INVOKAMET (canagliflozin) [reported separately through FY2022Q4] — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q4 2022Jan 1, 2023-19.6%+25.3 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
Q3 2022Oct 2, 2022-14.1%+27.2 ptsForm 8-K (a2022q3exhibit991.htm, filed 2022-10-18) ↗
Q2 2022Jul 3, 2022-21.8%-7.8 ptsForm 8-K (a2022q2exhibit991.htm, filed 2022-07-19) ↗
Q1 2022Apr 3, 2022-13.1%+3.0 ptsForm 8-K (a2022q1exhibit991.htm, filed 2022-04-19) ↗
Q4 2021Jan 2, 2022-44.9%-67.0 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗
Q3 2021Oct 3, 2021-41.3%-66.2 ptsForm 8-K (a2021q3exhibit991.htm, filed 2021-10-19) ↗
Q2 2021Jul 4, 2021-14.0%-17.1 ptsForm 8-K (a2021q2exhibit991final.htm, filed 2021-07-21) ↗
Q1 2021Apr 4, 2021-16.1%-3.2 ptsForm 8-K (a2021q1exhibit991final.htm, filed 2021-04-20) ↗
Q4 2020Jan 3, 202122.1%+43.9 ptsForm 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
Q3 2020Sep 27, 202024.9%+29.9 ptsForm 8-K (a2020q3exhibit991.htm, filed 2020-10-13) ↗
Q2 2020Jun 28, 20203.1%+20.0 ptsForm 8-K (a2020q2exhibit991.htm, filed 2020-07-16) ↗
Q1 2020Mar 29, 2020-12.9%+4.0 ptsForm 8-K (a2020q1exhibit991.htm, filed 2020-04-14) ↗
Q4 2019Dec 29, 2019-21.8%-8.1 ptsForm 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗
Q3 2019Sep 29, 2019-5.0%+22.6 ptsForm 8-K (a2019q3exhibit991.htm, filed 2019-10-15) ↗
Q2 2019Jun 30, 2019-16.9%+10.8 ptsForm 8-K (a2019q2exhibit9915.htm, filed 2019-07-16) ↗
Q1 2019Mar 31, 2019-16.9%-3.1 ptsForm 8-K (a2019q1exhibit9915.htm, filed 2019-04-16) ↗

Breakdown

What makes up INVOKANA / INVOKAMET [reported separately through

Cite this data

StockData. (2026). Johnson & Johnson INVOKANA / INVOKAMET [reported separately through (%), quarterly Q4 2017–Q4 2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-invokana-ops-yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.